SULF1 and telomere syndrome: Similarly, we find that the STS patient with mitigation of ADRB2 and SQSTM1 has poorer OS (Figures 3A, B), while the augmented levels of MAGED1, SRPK1, and SULF1 seem to account for a better prognosis in STS (Figures 3C-E).